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Background: The AKAP-Lbc scaffold coordinates cardiac hypertrophic signaling.
Results: PKA phosphorylation of Shp2 at Thr-73/Ser-189 inhibits tyrosine-phosphorylated ligand binding and PTP activity.
Conclusion:AKAP-LbcintegratesPKAandShp2signaling,andAKAP-Lbc-associatedShp2activityisreducedinhypertrophic
hearts following chronic -adrenergic stimulation.
Significance:PKAinhibitionofAKAP-Lbc-anchoredShp2activityisapreviouslyunrecognizedmechanismthatmaypromote
cardiac hypertrophy.
Pathologicalcardiachypertrophy(anincreaseincardiacmass
resulting from stress-induced cardiac myocyte growth) is a
major factor underlying heart failure. Src homology 2 domain-
containing phosphatase (Shp2) is critical for cardiac function
becausemutationsresultinginlossofShp2catalyticactivityare
associatedwithcongenitalcardiacdefectsandhypertrophy.We
identified a novel mechanism of Shp2 inhibition that may pro-
mote cardiac hypertrophy. We demonstrate that Shp2 is a com-
ponent of the protein kinase A anchoring protein (AKAP)-Lbc
complex. AKAP-Lbc facilitates PKA phosphorylation of Shp2,
whichinhibitsShp2phosphataseactivity.Weidentifiedtwokey
amino acids in Shp2 that are phosphorylated by PKA. Thr-73
contributes a helix cap to helix B within the N-terminal SH2
domain of Shp2, whereas Ser-189 occupies an equivalent posi-
tion within the C-terminal SH2 domain. Utilizing double
mutant PKA phosphodeficient (T73A/S189A) and phosphomi-
metic (T73D/S189D) constructs, in vitro binding assays, and
phosphatase activity assays, we demonstrate that phosphoryla-
tion of these residues disrupts Shp2 interaction with tyrosine-
phosphorylated ligands and inhibits its protein-tyrosine phos-
phatase activity. Overall, our data indicate that AKAP-Lbc
integrates PKA and Shp2 signaling in the heart and that AKAP-
Lbc-associated Shp2 activity is reduced in hypertrophic hearts
in response to chronic -adrenergic stimulation and PKA acti-
vation. Therefore, although induction of cardiac hypertrophy is
a multifaceted process, inhibition of Shp2 activity through
AKAP-Lbc-anchored PKA is a previously unrecognized mecha-
nism that may promote this compensatory response.
Localized regulation and integration of intracellular signal
transduction is critical for cardiac function. A pivotal mecha-
nism that regulates signal transduction pathways is the forma-
tion of complexes between signaling molecules and scaffold
proteins(1).ProteinkinaseAanchoringproteins(AKAPs)
4are
a diverse family of scaffold proteins that provide a framework
for the formation of multienzyme signaling complexes that
integrate cAMP signaling with other pathways (2, 3). All mem-
bersoftheAKAPfamilypossessaconservedPKAamphipathic
anchoring helix (4, 5) as well as binding sites for additional
signaling components (6). Importantly, these scaffold proteins
target unique signaling complexes to discrete subcellular loca-
tions, thereby generating substrate specificity (2). In the heart,
AKAPs play an essential role by integrating PKA signaling with
additional enzymes to modulate physiological and pathophysi-
ologicalprocesses,includingcardiacremodelingandthedevel-
opment of heart failure (7, 8).
Spatiotemporal regulation of signal transduction is integral
forpropercardiacfunction,andperturbationofthisregulation
can lead to heart failure. AKAPs play a crucial role in directing
PKA to several substrates important for cardiac function (6, 9,
10). Previous studies have shown that differential expression of
AKAPs may be a critical factor in the development of heart
failure (11). One such AKAP, AKAP-Lbc, is encoded by the
AKAP13 gene long transcript and is predominantly expressed
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 intheheart(12).Itsexpressionintheratheartisinducedunder
hypertrophic conditions, suggesting an important role in car-
diac hypertrophy (13). A similar increase in AKAP-Lbc expres-
sion has been observed in heart samples from patients with
hypertrophic cardiomyopathy compared with control, age-
matched, healthy samples (13). Furthermore, our previous
work revealed that AKAP-Lbc promotes cardiac hypertrophy
throughactivationofaproteinkinaseD1(PKD1)-mediatedsig-
naling pathway (13).
Cardiac myocytes respond primarily to an increased work-
loadbyincreasinginsize(hypertrophy).Cardiachypertrophyis
a means to decrease ventricular wall tension and increase car-
diac output and stroke volume. Initially, hypertrophy is a ben-
eficial compensatory process. However, prolonged hypertro-
phy is maladaptive, with the myocardium transitioning to
decompensation and cardiac failure. Multiple pathological
hypertrophicpathwaysconvergeonasetoftranscriptionalreg-
ulators to activate hypertrophic gene expression. Initiation of
this developmental gene-reprogramming paradigm is often
termedthefetalgeneresponse(14).These“fetal”cardiacgenes
encodeproteinsinvolvedincontraction,calciumhandling,and
metabolism, and their activation accompanies cardiac hyper-
trophy(15,16).Therefore,definingthesignalingeventsorches-
tratedbyAKAP-Lbcmayleadtotheidentificationofnewphar-
macological approaches for the treatment of heart failure.
In addition to demonstrating that AKAP-Lbc mobilizes a
prohypertrophic signaling pathway through PKD1, we also
demonstrated the importance of AKAP-Lbc-tethered PKA in
the induction of cardiac hypertrophy through knockdown/res-
cue experiments (13). Furthermore, we have shown that the
protein-tyrosine phosphatase Shp2 (PTPN11) interacts with
AKAP-Lbc and demonstrated that AKAP-Lbc integrates PKA
and Shp2 signaling in the heart (17). Interestingly, Shp2 is also
associated with the modulation of myocyte size, cardiomyopa-
thy, and heart failure (18–20). LEOPARD syndrome patients
most commonly manifest congenital heart defects and cardiac
hypertrophy because of mutations in the PTPN11 gene encod-
ingShp2thatgenerallyresultinimpairedShp2catalyticactivity
(21, 22). Furthermore, cardiomyocyte-specific genetic deletion
ofShp2resultsinrapiddevelopmentofdilatedcardiomyopathy
(23). Previously, we observed diminished Shp2 activity associ-
ated with AKAP-Lbc following chronic isoproterenol treat-
ment, which activates PKA and induces cardiac hypertrophy
(17). However, prior to this study, the mechanism by which
AKAP-Lbc inhibits Shp2 was unknown. Here we report that
AKAP-Lbc facilitates PKA phosphorylation of Shp2 at amino
acidresiduesThr-73andSer-189,therebyinhibitingitsprotein
tyrosine phosphatase (PTP) activity and disrupting its binding
to tyrosine-phosphorylated ligands. Although induction of
cardiac hypertrophy is a multifaceted process, inhibition of
Shp2 activity through enhanced PKA signaling represents a
previouslyunrecognizedmechanismcontributingtocardiac
hypertrophy.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Anti-GFP antibody (mouse,
1:1000) was from Clontech. Anti-FLAG M2 antibody (mouse,
1:1000) and anti--actinin (mouse, 1:500) were from Sigma.
Anti-phospho-PKA substrate (RRXS*/T*) antibody (rabbit,
1:1000) was from Cell Signaling Technology. Anti-phosphoty-
rosine antibody, clone 4G10 (mouse, 1:1000), and anti-GST
(mouse, 1:1000) were from EMD Millipore. Wild-type Shp2
mammalian expression constructs were provided by Dr. Gen-
Sheng Feng (University of California, San Diego). Mammalian
expression constructs for GAB1, GAB2, and constitutively active
Src (Y527F) were provided by Dr. Andrei Karginov (University of
Illinois at Chicago).
BacterialExpression—GSTandGST-Shp2-SH2domainpro-
teins were expressed as N-terminal GST-tagged fusions using
the pGEX-4T1 vector (Amersham Biosciences) in bacteria
(DH5) and purified by glutathione-Sepharose chromatogra-
phy (GE Healthcare). Bacterial cultures were grown overnight
at37 °C.Thefollowingday,bacterialcultureswerediluted1:10,
grown to an A600 of 0.6, and induced with 0.1 mM isopropyl
1-thio--D-galactopyranosidefor3hat37°C.Cellswereresus-
pended in MTPBS (16 mM Na2HPO4,4m M NaH2PO4-H2O,
150mMNaCl,50mMEDTA,and1%TritonX-100(pH7.3))and
sonicated, and then insoluble debris was removed by centrifu-
gation. The supernatant was then incubated with glutathione-
Sepharose beads (GE Healthcare) for1ha t4° C .Beads were
then washed three times with MTPBS.
Transfections, Coimmunoprecipitations, and Pulldowns—
HEK293Tcellsweretransfectedandlysedincelllysisbuffer(10
mM sodium phosphate buffer (pH 6.95), 150 mM NaCl, 5 mM
EDTA, 5 mM EGTA, and 1% Triton X-100) as described previ-
ously (24). For phosphorylation experiments, the phosphatase
inhibitor microcystin-LR was included (100 nM). Lysates were
incubatedonicefor10minandcentrifugedat20,000gfor15
min at 4 °C. Cleared lysates were incubated with antibodies for
1 h at 4 °C with rocking, followed by precipitation of antibody-
antigencomplexeswithproteinA/G-agarose.Immunoprecipi-
tates were washed 5  1 ml in lysis buffer, eluted in SDS-PAGE
sample buffer, and separated by SDS-PAGE. GST pulldowns
were performed similarly, except that protein complexes were
isolated by incubation with glutathione-Sepharose for1ha t
4 °C.
Cell Culture, Immunocytochemistry, and Cell Imaging—
Preparation of primary neonatal rat ventricular myocytes and
confocalmicroscopyexperimentswereperformedasdescribed
previously (13). Neonatal rat ventricular myocytes were elec-
troporated using a modified Amaxa Nucleofector protocol.
After incubation at 37 °C for 48 h post-electroporation, cells
were washed twice with PBS and fixed in 3.7% paraformalde-
hyde in PBS, followed by staining for -actinin. The secondary
antibodies used were from Invitrogen. Confocal images were
acquired using a Carl Zeiss LSM 510 mounted on an Axiovert
100 Mmicroscope.Imageswereobtainedusinga488-nmargon
laser for GFP and 561 nm for red fluorescent protein with a
Plan-Apochromat 63/1.4 oil immersion objective lens. The
cell area of -actinin and GFP double-positive myocytes was
quantified using ImageJ as described previously (13).
In Vitro PTP Activity Assay—Following immunoprecipita-
tion of either AKAP-Lbc or Shp2, immune complexes were
washed five times with IP buffer (10 mM sodium phosphate
buffer (pH 6.95), 150 mM NaCl, 5 mM EDTA, 5 mM EGTA, and
1% Triton X-100) before being resuspended in phosphatase
PKAPhosphorylationInhibitsShp2PTPActivity
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 assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM DTT, 2 mM
Na2EDTA,and0.01%Brij-35(pH7.5)).Thephosphataseassay
was carried out in a total reaction volume of 50 l using 30 M
fluoresceindiphosphateassubstrate.Aftera20-minincubation
at30 °C,thesupernatantwastransferredtoa96-wellplate,and
phosphatase activity was measured using a PHERAstar FS
microplate reader with excitation at 485 nm and emission at
520 nm. For calibration of PTP activity using this assay, T cell
PTP (New England Biolabs) was serially diluted and used for
assay as described above. Fluorescence intensity was measured
for known amounts of enzyme ranging from 0–500 milliunits
ofspecificactivity.Oneunitisdefinedastheamountofenzyme
thathydrolyzes1nmolofp-nitrophenylphosphate(50mM)in1
min at 30 °C in a total reaction volume of 50 l.
Structural Analysis—Structural alignments were performed
using the secondary structure matching superimpose tool in
Coot (25). Three-dimensional schematic representations of
SHP-2 were generated using PyMOL (Schroedinger LLC).
Statistical Analysis of Data—All data are expressed as
mean  S.E. Differences in quantitative variables were exam-
ined by one-way analysis of variance or an unpaired two-tailed
Student’sttest.p0.05wasconsideredsignificant(*,p0.05;
**, p  0.01; ***, p  0.001). All analyses were performed using
InStat.
RESULTS
AKAP-Lbc-associated Shp2 Activity Is Increased under Basal
Conditions—We have demonstrated previously that Shp2 is a
component of the AKAP-Lbc complex (17). Under conditions
ofenhancedPKAsignaling,suchaschronic-adrenergicstim-
ulation or forskolin/IBMX treatment, AKAP-Lbc facilitates
PKA phosphorylation of Shp2, which inhibits its PTP activity
(17).TodeterminewhetherassociationwithAKAP-Lbcaffects
the specific activity of Shp2 under basal conditions, we per-
formed in vitro PTP activity assays and compared the specific
activity of total Shp2 versus Shp2 associated with AKAP-Lbc.
FLAG-tagged Shp2 was coexpressed in HEK293T cells with
eitherFLAG-GFPorGFP-AKAP-Lbc(Fig.1).Followingimmu-
noprecipitation, PTP activity was measured (Fig. 1A) and nor-
malized to the amount of Shp2 in the IP (Fig. 1B). Similarly,
GFP-tagged AKAP-Lbc was immunoprecipitated, and PTP
activity was assayed and normalized to the amount of Shp2
present in the IP. The specific PTP activity of AKAP-Lbc-asso-
ciatedShp2wasincreased4-fold(p0.045)comparedwiththe
total Shp2 immunoprecipitated from whole cell lysate.
PKA Phosphorylation of Sites Thr-73 and Ser-189 Inhibits
Shp2Activity—Todeterminewhichaminoacidresidueswithin
Shp2 are phosphorylated by PKA, we first identified potential
candidate sites on the basis of the consensus PKA phosphory-
lation motif (R-R-X-Ser(P)/Thr(P)) using Scansite 2.0 (26). We
identified three candidate PKA phosphorylation sites (Thr-
73, Ser-189, and Ser-326) that were individually mutated to
alanine. WT or mutant Shp2 was coexpressed with AKAP-
LbcinHEK293Tcells,andthencellsweretreatedwitheither
vehicle or forskolin/IBMX for 20 min. Following immuno-
precipitation of AKAP-Lbc, phosphorylation of Shp2 was
examined using an antibody that recognizes the consensus
PKAphosphorylationsitesR-R-X-Ser(P)/Thr(P).Treatment
with forskolin/IBMX resulted in PKA-mediated phosphory-
lation of Shp2. Importantly, phosphorylation was dimin-
ished in the T73A and S189A mutants but not in the S326A
mutant (Fig. 2A).
To determine the effect of PKA phosphorylation on Shp2
activity, we measured the PTP activity of WT, T73A, S189A,
andS326AversionsofShp2inAKAP-Lbcimmunoprecipitates
(Fig. 2B). Under basal conditions, no change in AKAP-Lbc-
associatedShp2activitywasobservedaftermutationofthecan-
didate sites. Treatment with forskolin/IBMX inhibited AKAP-
Lbc-associated WT Shp2 activity as well as that of the S326A
FIGURE 1. The specific activity of AKAP-Lbc-associated Shp2 is increased under basal conditions. A, HEK293T cells were transfected with FLAG-
Shp2, GFP-AKAP-Lbc plus FLAG-Shp2, or FLAG-GFP vector as a control. Shp2 or AKAP-Lbc was isolated from cell lysates using anti-FLAG-antibody or
anti-GFP-antibody, respectively. Immunoprecipitates were washed, and PTP activity was measured by a fluorometric in vitro assay. Parallel control
anti-FLAGandanti-GFPIPswereassayedusinganequalamountoflysate(2mg)fromcellsexpressingFLAG-GFPvector.ResultsshowmeanPTPactivity
perIP S.E.afternormalizingtotheamountofShp2intheIP.BandintensitieswerequantifiedusingImageJandwerewithinthelineardynamicrange
ofdetection.Allassayswereperformedintriplicateforthreeindependentexperiments.Differencesinquantitativevariableswereexaminedbyanalysis
ofvariance.*,p  0.05.B,WesternblotsshowingcorrespondinglevelsofShp2,AKAP-Lbc,andcontrolFLAG-GFPvectorinsamplesusedforPTPactivity
measurement in A.
PKAPhosphorylationInhibitsShp2PTPActivity
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 mutant. However, mutation of either Thr-73 or Ser-189 to
alanine reduced this inhibition 2-fold (p  0.035) and 1.7-
fold (p  0.044), whereas mutation of Ser-326 to alanine did
not alter the inhibition of Shp2 following PKA activation.
This difference in Shp2 activity is not due to changes in the
association of the Shp2 mutants with AKAP-Lbc because
equivalentamountsofeachShp2proteinwerepresentinthe
AKAP-Lbc IPs (Fig. 2A).
ThecombinedmutationofT73AandS189AinShp2elim-
inated PKA-induced phosphorylation of Shp2 (Fig. 2C).
Consistent with the lack of PKA phosphorylation, the phos-
phatase activity of this phosphodefective Shp2 mutant was
unaffected following PKA activation (Fig. 2D). We also gen-
erated a phosphomimetic version of Shp2 by mutation of
Thr-73andSer-189toaspartate.AlthoughPKA-inducedphos-
phorylation of the Shp2 T73D/S189D mutant was also
impaired, the AKAP-Lbc-associated PTP activity of this phos-
phomimetic mutant was similar to that of WT Shp2 following
PKA activation, regardless of whether PKA was activated in
cells (Fig. 2D). Therefore, the T73A/S189A mutations block
PKA-mediated phosphorylation and inhibition of AKAP-Lbc-
associated Shp2, whereas the T73D/S189D phosphomimetic
mutationsleadtoimpairedAKAP-Lbc-associatedShp2activity
under basal conditions.
Shp2 T73D/S189D SH2 Domains Display Altered Ligand
Specificity—The location of the PKA phosphorylation sites in
relation to the Shp2 N-terminal (N) and C-terminal (C) SH2
domainsandthePTPdomainareshownincontextofthestruc-
ture of Shp2 (Fig. 3A). The hydroxyl group of the Thr-73 side
chainparticipatesinahelix-cappinginteractionwiththemain-
chain amide group of Glu-76 at the N terminus of helix Bi n
the “N” SH2 domain. Similarly, the hydroxyl group of the Ser-
189 side chain forms a helix cap with the main-chain amide of
Asp-192 at the N terminus of helix B in the “C” SH2 domain.
SequencealignmentoftheNandCSH2domainsdemonstrates
that Thr-73 and Ser-189 are located at analogous positions
within their respective SH2 domains (Fig. 3B). The two amino
acids are structurally equivalent in that both form the first
position of an N-capping motif that precedes helix Bo ft h e
SH2 domain (Fig. 3C). The most elegant way to explain the
effects of dual Thr-73/Ser-189 phosphorylation on Shp2 activ-
ity is that phosphorylation in both cases would be expected to
break the N-capping interaction and lead to destabilization/
melting of helix B. A stable B helix is required for phospho-
tyrosine recruitment (Fig. 3D). Therefore, PKA phosphoryla-
tion may reduce Shp2 activation by reducing the binding
affinity of phosphotyrosine ligands to each SH2 domain by the
same mechanism.
FIGURE 2. Phosphorylation of Shp2 residues Thr-73 and Ser-189 by PKA regulates Shp2 activity. A, Scansite was used to identify consensus PKA phos-
phorylation (R-R-X-Ser(P)/Thr(P)) sites in Shp2, yielding three predicted residues: Thr-73, Ser-189, and Ser-326. HEK293T cells were transfected with wild-type
orSer/Thr-to-AlamutantShp2expressionconstructs.Priortolysis,cellsweretreatedfor20minwitheitherdimethylsulfoxide(DMSO,vehicle)orwithforskolin
(Fsk,20M)andIBMX(75M)toactivatePKA.AKAP-Lbcwasisolatedfromcelllysatesusinganti-GFP-antibody,andimmunecomplexeswereusedforinvitro
measurementofPTPactivity.WesternblotloadingcontrolsdemonstratecomparableexpressionofGFP-AKAP-LbcandassociatedFLAG-Shp2-WTandFLAG-
Shp2mutantsforallassays.Blotswereprobedwithanti-PKA-phospho-substrateantibodytoexaminetheextentofShp2phosphorylation.B,quantificationof
three independent in vitro PTP assays. *, p  0.05. C, HEK293T cells were transfected with AKAP-Lbc and FLAG-Shp2-WT or FLAG-Shp2 T73A/S189A (PKA
phosphodeficient) or FLAG-Shp2 T73D/S189D (PKA phosphomimetic) expression vectors. Prior to lysis, cells were treated for 20 min with either dimethyl
sulfoxide(vehicle)orwithforskolin/IBMXtoactivatePKA.AKAP-Lbcwasisolatedfromcelllysatesusinganti-GFP-antibody,andimmunecomplexeswereused
forinvitromeasurementofPTPactivity.WesternblotloadingcontrolsdemonstratedcomparableexpressionofAKAP-LbcandassociatedShp2-WTandShp2
mutantsforallassays.Blotswereprobedwithanti-PKAphosphosubstrateantibodytoexaminetheextentofShp2phosphorylation.D,quantificationofthree
independent in vitro PTP assays. *, p  0.05.
PKAPhosphorylationInhibitsShp2PTPActivity
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 To determine whether PKA phosphorylation of Shp2 dis-
rupts binding to tyrosine-phosphorylated ligands, we per-
formedinvitropulldownassaysusingbacteriallyexpressedWT
or mutant (T73A/S189A or T73D/S189D) GST-tagged Shp2
SH2 domains. The scaffolding adaptor proteins Grb2-associ-
tated binding protein 1 (GAB1) and Grb2-associated binding
protein 2 (GAB2) as well as PKD1 were coexpressed with con-
stitutively active Src tyrosine kinase in HEK293T cells. Lysates
from these cells were subsequently used as inputs for pulldown
with GST-SH2. The pulldown experiments demonstrated that
the T73A/S189A double mutation has a negligible effect on
Shp2 SH2 binding to GAB1 (Fig. 4, A and B), GAB2 (Fig. 4, C
andD),orPKD1(Fig.4,EandF).Conversely,theT73D/S189D
double mutation reduced Shp2 binding to GAB1 5.7-fold (Fig.
FIGURE 3. Modeling PKA phosphorylation of Shp2. A, schematic representation of the full-length Shp2 structure (PDB code 2SHP) showing the location of
twoPKAphosphorylationsitesinrelationtothefirstNSH2domain(orange),thesecondCSH2domain(green),andthePTPdomain(blue).Theleftboxshows
thelocationofThr-73.ThehydroxylgroupoftheThr-73sidechainparticipatesinahelix-cappinginteractionwiththemainchainamidegroupofGlu-76atthe
NterminusofhelixBintheNSH2domain.ThreeresiduesareinthevicinitythathavethepotentialtointeractwithThr(P)-73:Arg-498andGln-255inthePTP
domain and Tyr-63 in the N SH2 domain. The right box shows the location of Ser-189. The hydroxyl group of the Ser-189 side chain forms a helix cap with the
main-chainamideofAsp-192attheNterminusofhelixBintheCSH2domain.PhosphorylationatSer-189likelydestabilizestwointeractionsinadditionto
disruptingthehelixcap:ahydrophobicpackinginteractionbetweenSer-189andAla-105andasaltbridgebetweenArg-5andAsp-192.B,sequencealignment
oftheNandCSH2domainsindicatesthatThr-73andSer-189areatequivalentpositionswithintheirrespectiveSH2domains.Bothaminoacidsformthefirst
position of an N-capping motif that precedes helix B. C, superposition of the N (orange)a n dC( green) SH2 domains further demonstrates the structural
equivalenceofthetwoaminoacids.PhosphorylationinbothcasescanbeexpectedtobreaktheN-cappinginteractionandleadtodestabilizationofhelixB.
D, superposition of the SHP-2 N SH2 domain in the presence (green, PDB code 1AYA) and absence (red, PDB code 2SHP) of phosphotyrosine ligand (black)
indicates that Ser/Thr at the N-terminal cap of helix B is not highly dynamic. Furthermore, phosphorylation of Thr-73/Ser-189 will not sterically hinder the
recruitment of phospholigand.
PKAPhosphorylationInhibitsShp2PTPActivity
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 4, A and B; p  0.011), to GAB2 2.7-fold (Fig. 4, C and D; p 
0.025), and to PKD1 1.7-fold (Fig. 4, E and F; p  0.028).
The Shp2-T73A/S189A Mutant Inhibits Isoproterenol-in-
duced Tyrosine Phosphorylation of PKD1 in the AKAP-Lbc
Complex—It has been reported that the tyrosine kinases Src
and Abl phosphorylate PKD1 (27–29), suggesting that tyrosine
phosphorylation within the pleckstrin homology domain of
PKD1 induces a conformational change, promoting PKC
recruitment and leading to activation of PKD1. To determine
whetherisoproterenol(ISO)-stimulatedPKAactivationresults
in enhanced tyrosine phosphorylation of PKD1 by inhibiting
Shp2 in the AKAP-Lbc complex, we utilized HEK293 cells sta-
bly expressing the 1-adrenergic receptor (30). These cells
were transiently transfected with vectors encoding AKAP-Lbc,
PKD1, and either Shp2 WT, Shp2-T73A/S189A, or Shp2-
T73D/S189D. Analysis of AKAP-Lbc-associated PKD1 tyro-
sine phosphorylation revealed that Shp2 WT enhanced ISO-
induced PKD1 phosphorylation. Interestingly, expression of
theShp2-T73A/S189AmutantabolishedtheeffectofISOstim-
ulation on PKD1 phosphorylation (Fig. 5). In contrast, expres-
sion of the Shp2-T73D/S189D mutant enhanced basal tyrosine
phosphorylation of PKD1 in the AKAP-Lbc complex 2-fold
(p0.014),andtreatmentwithISOdidnotfurtherincreasethe
level of PKD1 phosphorylation (Fig. 5).
Overexpression of Shp2 T73A/S189A Inhibits Isoproterenol-
inducedCardiacHypertrophy—Chronic-adrenergicreceptor
stimulation by ISO was used as an in vitro cellular model to
study hypertrophic PKA signaling. Neonatal rat ventricular
myocytesweretransfectedwithGFP-taggedvectorsexpressing
eitherShp2-WT,Shp2-T73A/S189A,orShp2-T73D/S189D.In
myocytes expressing GFP-Shp2-WT, treatment with ISO
increased cellular size 1.8-fold (Fig. 6, p  0.001). This hyper-
trophic effect of ISO was inhibited by expression of Shp2-
T73A/S189A. However, expression of the Shp2 phosphomi-
FIGURE4.MutationofresiduesThr-73andSer-189toAspdisruptsShp2bindingtotyrosine-phosphorylatedligands.A,associationbetweentheGAB1
and wild-type Shp2 (WT) or PKA phosphodeficient Shp2 (T73A/S189A) or PKA phosphomimetic Shp2 (T73D/S189D) SH2 domains was assessed by pulldown
assaysusingglutathione-Sepharosebead-boundbacterialfusionproteins.GST-Shp2SH2proteinswereincubatedwithlysatesfromHEK293Tcellstransfected
with Venus-GAB1 and constitutively active Src expression vectors. Proteins bound to beads were immunoblotted for phosphotyrosine (-4G10) and GST. B,
bandintensitieswerequantifiedusingImageJ,andrelativebindingwasdeterminedfromtheratiosofphosphorylatedVenus-GAB1toGST-Shp2SH2input.*,
p  0.05. C, the association between GAB2 and wild-type Shp2 or mutant Shp2 SH2 domains was assessed as above. GST-Shp2 SH2 proteins were incubated
withlysatesfromHEK293TcellstransfectedwithVenus-GAB2andconstitutivelyactiveSrcexpressionvectors.Proteinsboundtobeadswereimmunoblotted
for phosphotyrosine and GST. D, band intensities were quantified using ImageJ, and relative binding was determined from the ratios of phosphorylated
Venus-GAB2toGST-Shp2SH2input.*,p0.05.E,theassociationbetweenPKD1andwild-typeShp2ormutantShp2SH2domainswasassessed.GST-Shp2SH2
proteinswereincubatedwithlysatesfromHEK293TcellstransfectedwithGFP-PKD1andconstitutivelyactiveSrcexpressionvectors.Proteinsboundtobeads
wereimmunoblottedforphosphotyrosineandGST.F,bandintensitieswerequantifiedusingImageJ,andrelativebindingwasdeterminedfromtheratiosof
phosphorylated GFP-PKD1 to GST-Shp2 SH2 input. *, p  0.05.
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 meticmutantShp2-T73D/S189Dincreasedmyocytesizeunder
basal conditions 1.38-fold (p  0.011) with no further increase
in size after ISO treatment (Fig. 6).
DISCUSSION
We have demonstrated previously that Shp2 is a component
of the AKAP-Lbc complex and that AKAP-Lbc facilitates PKA
phosphorylationofShp2(17).Inthisreport,weidentifytwokey
amino acids in Shp2 that are phosphorylated by PKA, Thr-73
and Ser-189. We demonstrate that phosphorylation of these
residuesdisruptsShp2interactionwithtyrosine-phosphorylat-
ed ligands and inhibits its protein-tyrosine phosphatase activ-
ity. Furthermore, our data indicate that the phosphomimetic
mutant of Shp2, Shp2-T73D/S189D, induces a significant
increase in the size of neonatal rat cardiomyocytes in the
absence of ISO stimulation.
Our previous mapping experiments have shown that Shp2
binds predominately to a central region of AKAP-Lbc (17).
Under conditions of enhanced PKA activity, Shp2 association
with the AKAP-Lbc complex facilitates PKA phosphorylation
and inhibition of Shp2 activity (17). This study demonstrates
that, under basal conditions, Shp2-specific activity is enhanced
withintheAKAP-Lbccomplex,indicatingthatShp2bindingto
AKAP-Lbcincreasesitsactivity.Takentogether,thesefindings
suggest that the AKAP-Lbc complex plays a critical role in reg-
ulating Shp2 activity and may mediate a negative feedback
mechanism under conditions of increased PKA activity.
Studies of AKAP-Lbc-associated activity of WT and Shp2
mutants revealed the criticality of residues 73 and 189. Muta-
tion of Thr-73/Ser-189 to Ala or Asp abolished phosphoryla-
tion by PKA. Additionally, the T73A/S189A mutations block
PKA-mediated inhibition of Shp2 activity, whereas the phos-
phomimeticmutations(T73D/S189D)leadtoimpairedAKAP-
Lbc-associated Shp2 activity under basal conditions. Together,
these results indicate that sites Thr-73 and Ser-189 are phos-
phorylated by PKA, inhibiting Shp2 activity. Further investiga-
tion of the mechanism of PKA-mediated Shp2 inhibition dem-
onstrated that the T73A/S189A mutations do not significantly
alter Shp2 SH2 binding to phosphorylated GAB1, GAB2, and
PKD1.However,thephosphomimeticT73D/S189Dmutations
resultedinimpairedphosphotyrosinebindingbytheShp2SH2
domains, suggesting that PKA phosphorylation of Shp2 modi-
fies its ligand specificity.
We propose that dual Thr-73/Ser-189 phosphorylation
affectsShp2activitybyamechanisminwhichphosphorylation
at both sites disrupts N-capping interactions with the SH2
domains, leading to destabilization/melting of helix B. A sta-
bleBhelixisrequiredforphosphotyrosinerecruitmentbythe
SH2 domains. Therefore, PKA phosphorylation may inhibit
Shp2 activation by reducing the binding affinity of phosphoty-
rosine ligands to each SH2 domain by a similar mechanism.
Interestingly, Thr-73 is inaccessible when Shp2 maintains an
inactive conformation (31). Therefore, phosphorylation by
PKA at this site would presumably only be possible following
activationofthephosphatase,which,aswedemonstratedhere,
occurs within the AKAP-Lbc complex under basal conditions.
AnotherpotentialcontributorymechanismisthatThr(P)-73
interacts with a phosphobinding site on the PTP domain,
including residues Arg-498 and Gln-255, thereby stabilizing
Shp2 in its inactive conformation. Additionally, phosphoryla-
tion of Ser-189 may disrupt interactions that link the N and C
SH2 domains to reduce cooperative binding of phosphoty-
rosine ligands to the two SH2 domains.
Interestingly, mutation of residue Thr-73 to Ile has been
observed in Noonan syndrome and juvenile myelomonocytic
leukemiapatients(32).TheT73Imutationleadstohigherbasal
Shp2 activity by shifting the basal equilibrium constant toward
the active state. Activation by insulin receptor substrate 1
(IRS-1) is not greatly affected (33). This suggests that the
branchedaliphaticsidechainofIlecannotbeaccommodatedin
the pocket of the phosphatase domain in proximity to Tyr-63,
Arg-498 and Gln-255. Both branches of the Ile side chain
extendtotheposition,whereasbothThrandThr(P)haveone
branch terminating earlier with a methyl group at the  posi-
FIGURE 5. Inhibition of Shp2 by PKA enhances tyrosine phosphorylation
of PKD1 in the AKAP-Lbc complex. A, HEK293 cells stably expressing the
1-adrenergicreceptorweretransfectedwiththeGFP-AKAP-Lbc,GST-PKD1,
and either FLAG-Shp2-WT or FLAG-Shp2 T73A/S189A or FLAG-Shp2 T73D/
S189D expression vectors. Prior to lysis, cells were treated for 20 min with
either dimethyl sulfoxide (vehicle) or ISO (10 M) to activate PKA. AKAP-Lbc
wasisolatedfromcelllysatesusinganti-GFP-antibody.IPswerewashed,and
theboundproteinswereseparatedbySDS-PAGEandtransferredtonitrocel-
lulose. Detection of tyrosine-phosphorylated GST-PKD1, total GST-PKD1,
GFP-AKAP-Lbc, and FLAG-Shp2 was carried out by immunoblotting. B, band
intensities were quantified from four independent experiments using
ImageJ, and relative tyrosine-phosphorylation of GST-PKD1 was determined
fromtheratiooftyrosine-phosphorylatedGST-PKD1tototalGST-PKD1inthe
IP. *, p  0.05.
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 tion. Ile-73, therefore, likely disrupts packing between the
N-terminal SH2 domain and the phosphatase domain.
PKA,AKAP-Lbc,andShp2playprominentrolesinsignaling
mechanisms leading to the induction of cardiac hypertrophy.
Mutations resulting in loss of Shp2 catalytic activity are associ-
atedwithcongenitalheartdefectsandcardiachypertrophy(21,
22). AKAP-Lbc is also implicated in cardiac hypertrophic sig-
naling, and we have shown that AKAP-Lbc-tethered PKA is
important for the induction of cardiomyocyte hypertrophy
(13). Consistent with the observation that mice deficient in
PKA-Careresistanttohypertrophicstimuli(34),currentdata
from our laboratory indicate that specific PKA inhibition abol-
ishesISO-inducedcardiomyocytehypertrophy,demonstrating
the primary contribution of PKA (35). The results of this study
demonstrate that the hypertrophic effect of ISO is inhibited by
expression of the Shp2 T73A/S189A mutant, whereas expres-
FIGURE 6. A, neonatal rat ventricular myocytes were transfected with a GFP-tagged wild-type Shp2 (WT), PKA phosphodeficient Shp2 (T73A/S189A), or PKA
phosphomimeticShp2(T73D/S189D)expressionvectorandthentreatedwitheitherdimethylsulfoxideorISOfor48htoinducehypertrophy.Cellswerefixed,
permeabilized, and stained with -actinin for cell imaging. Representative images are shown. B, cardiomyocytes with both -actinin staining and GFP
expression were selected for cell size measurements and quantified. Data are expressed as mean  S.E. The number of cells counted is indicated.
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 sion of the T73D/S189D mutant significantly increases myo-
cyte size in the absence of ISO stimulation. These results sug-
gest that PKA phosphorylation of Shp2 at Thr-73 and Ser-189
contributes to -adrenergic receptor-induced cardiomyocyte
hypertrophy.
WehavedemonstratedpreviouslythatAKAP-Lbcfacilitates
theactivationofPKD1inresponsetohypertrophicstimuli(24).
Activated PKD1 then phosphorylates class II histone deacety-
lases to promote their nuclear export, leading to the derepres-
sion of the transcription factor MEF2, resulting in cardiac
hypertrophy and tissue remodeling through MEF2-dependent
transcription of hypertrophic genes (13). Others have shown
that PKD1 conditional knockout mice are resistant to ISO-de-
pendent hypertrophy (36). Moreover, it has been reported that
tyrosine phosphorylation within the pleckstrin homology
domain of PKD1 enhances its catalytic activity (29). Here we
demonstrate that ISO stimulates tyrosine phosphorylation of
AKAP-Lbc-associatedPKD1inHEK293cellsstablyexpressing
the 1-adrenergic receptor. The Shp2 T73A/S189A mutant
inhibits ISO-induced PKD tyrosine phosphorylation, whereas
the Shp2 phosphomimetic mutant increases the basal tyrosine
phosphorylation of PKD1 in the AKAP-Lbc complex. Taken
together,ourdatasuggestthatShp2intheAKAP-Lbccomplex
maintains PKD in the dephosphorylated state and that, upon
PKA activation, AKAP-Lbc facilitates PKA phosphorylation
and inhibition of Shp2, thereby allowing enhanced PKD1 tyro-
sine phosphorylation and activation.
Inconclusion,weidentifiedanovelmechanismofShp2inhi-
bitionthatmaypromotecardiachypertrophy.AKAP-Lbcfacil-
itatesPKAphosphorylationofShp2,whichinhibitsShp2phos-
phatase activity. We identified two critical amino acids in Shp2
that are phosphorylated by PKA. We demonstrate that dual
phosphorylation of Thr-73/Ser-189 disrupts Shp2 interaction
with tyrosine-phosphorylated ligands and inhibits its protein
tyrosinephosphataseactivity.Interestingly,weandothershave
observed up-regulation of AKAP-Lbc expression under hyper-
trophic conditions (13, 17, 37). We speculate that this increase
inAKAP-LbclevelsmayfacilitatetheintegrationofPKA,Shp2,
andPKD1signalingintheheart.Althoughinductionofcardiac
hypertrophyisamultifacetedprocess,inhibitionofShp2activ-
ity through AKAP-Lbc-anchored PKA is a previously unrecog-
nized mechanism that may promote cardiac hypertrophy in
response to chronic -adrenergic stimulation.
Acknowledgments—We thank Dr. Gen-Sheng Feng for the FLAG-
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GAB1, Venus-GAB2, and Myc-Src (Y527F) expression constructs.
REFERENCES
1. Scott, J. D., and Pawson, T. (2009) Cell signaling in space and time: where
proteins come together and when they’re apart. Science 326, 1220–1224
2. Wong,W.,andScott,J.D.(2004)AKAPsignallingcomplexes:focalpoints
in space and time. Nat. Rev. Mol. Cell Biol. 5, 959–970
3. Carnegie, G. K., Means, C. K., and Scott, J. D. (2009) A-kinase anchoring
proteins: from protein complexes to physiology and disease. IUBMB Life
61, 394–406
4. Gold,M.G.,Lygren,B.,Dokurno,P.,Hoshi,N.,McConnachie,G.,Taskén,
K., Carlson, C. R., Scott, J. D., and Barford, D. (2006) Molecular basis of
AKAP specificity for PKA regulatory subunits. Mol. Cell 24, 383–395
5. Kinderman,F.S.,Kim,C.,vonDaake,S.,Ma,Y.,Pham,B.Q.,Spraggon,G.,
Xuong, N. H., Jennings, P. A., and Taylor, S. S. (2006) A dynamic mecha-
nism for AKAP binding to RII isoforms of cAMP-dependent protein ki-
nase. Mol. Cell 24, 397–408
6. Pidoux, G., and Taskén, K. (2010) Specificity and spatial dynamics of pro-
tein kinase A signaling organized by A-kinase-anchoring proteins. J. Mol.
Endocrinol. 44, 271–284
7. Mauban, J. R., O’Donnell, M., Warrier, S., Manni, S., and Bond, M. (2009)
AKAP-scaffolding proteins and regulation of cardiac physiology. Physiol-
ogy 24, 78–87
8. Carnegie,G.K.,andBurmeister,B.T.(2011)A-kinaseanchoringproteins
that regulate cardiac remodeling. J. Cardiovasc. Pharmacol. 58, 451–458
9. Diviani, D. (2008) Modulation of cardiac function by A-kinase anchoring
proteins. Curr. Opin. Pharmacol. 8, 166–173
10. Welch, E. J., Jones, B. W., and Scott, J. D. (2010) Networking with AKAPs:
context-dependent regulation of anchored enzymes. Mol. Interv. 10,
86–97
11. Aye,T.T.,Soni,S.,vanVeen,T.A.,vanderHeyden,M.A.,Cappadona,S.,
Varro, A., de Weger, R. A., de Jonge, N., Vos, M. A., Heck, A. J., and
Scholten, A. (2012) Reorganized PKA-AKAP associations in the failing
human heart. J. Mol. Cell. Cardiol. 52, 511–518
12. Diviani,D.,Soderling,J.,andScott,J.D.(2001)AKAP-Lbcanchorsprotein
kinase A and nucleates G 12-selective Rho-mediated stress fiber forma-
tion. J. Biol. Chem. 276, 44247–44257
13. Carnegie, G. K., Soughayer, J., Smith, F. D., Pedroja, B. S., Zhang, F., Divi-
ani,D.,Bristow,M.R.,Kunkel,M.T.,Newton,A.C.,Langeberg,L.K.,and
Scott, J. D. (2008) AKAP-Lbc mobilizes a cardiac hypertrophy signaling
pathway. Mol. Cell 32, 169–179
14. Depre, C., Shipley, G. L., Chen, W., Han, Q., Doenst, T., Moore, M. L.,
Stepkowski, S., Davies, P. J., and Taegtmeyer, H. (1998) Unloaded heart in
vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med. 4,
1269–1275
15. Frey, N., and Olson, E. N. (2003) Cardiac hypertrophy: the good, the bad,
and the ugly. Annu. Rev. Physiol. 65, 45–79
16. Heineke,J.,andMolkentin,J.D.(2006)Regulationofcardiachypertrophy
by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589–600
17. Burmeister,B.T.,Taglieri,D.M.,Wang,L.,andCarnegie,G.K.(2012)Src
homology 2 domain-containing phosphatase 2 (Shp2) is a component of
the A-kinase-anchoring protein (AKAP)-Lbc complex and is inhibited by
proteinkinaseA(PKA)underpathologicalhypertrophicconditionsinthe
heart. J. Biol. Chem. 287, 40535–40546
18. Nakamura,T.,Colbert,M.,Krenz,M.,Molkentin,J.D.,Hahn,H.S.,Dorn,
G. W., 2nd, and Robbins, J. (2007) Mediating ERK 1/2 signaling rescues
congenital heart defects in a mouse model of Noonan syndrome. J. Clin.
Invest. 117, 2123–2132
19. Krenz, M., Gulick, J., Osinska, H. E., Colbert, M. C., Molkentin, J. D.,
and Robbins, J. (2008) Role of ERK1/2 signaling in congenital valve
malformations in Noonan syndrome. Proc. Natl. Acad. Sci. U.S.A. 105,
18930–18935
20. Nakamura, T., Gulick, J., Pratt, R., and Robbins, J. (2009) Noonan syn-
dromeisassociatedwithenhancedpERKactivity,therepressionofwhich
can prevent craniofacial malformations. Proc. Natl. Acad. Sci. U.S.A. 106,
15436–15441
21. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., and Neel, B. G.
(2006)PTPN11(Shp2)mutationsinLEOPARDsyndromehavedominant
negative, not activating, effects. J. Biol. Chem. 281, 6785–6792
22. Stewart, R. A., Sanda, T., Widlund, H. R., Zhu, S., Swanson, K. D., Hurley,
A. D., Bentires-Alj, M., Fisher, D. E., Kontaridis, M. I., Look, A. T., and
Neel, B. G. (2010) Phosphatase-dependent and -independent functions of
Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
Dev. Cell 18, 750–762
23. Kontaridis,M.I.,Yang,W.,Bence,K.K.,Cullen,D.,Wang,B.,Bodyak,N.,
Ke, Q., Hinek, A., Kang, P. M., Liao, R., and Neel, B. G. (2008) Deletion of
Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via ef-
fects on the extracellular signal-regulated kinase/mitogen-activated pro-
tein kinase and RhoA signaling pathways. Circulation 117, 1423–1435
24. Carnegie, G. K., Smith, F. D., McConnachie, G., Langeberg, L. K., and
Scott, J. D. (2004) AKAP-Lbc nucleates a protein kinase D activation scaf-
PKAPhosphorylationInhibitsShp2PTPActivity
12066 JOURNALOFBIOLOGICALCHEMISTRY VOLUME290•NUMBER19•MAY8,2015
 
a
t
 
U
C
L
 
L
i
b
r
a
r
y
 
S
e
r
v
i
c
e
s
 
o
n
 
J
u
l
y
 
2
9
,
 
2
0
1
5
h
t
t
p
:
/
/
w
w
w
.
j
b
c
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 fold. Mol. Cell 15, 889–899
25. Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K. (2010) Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501
26. Obenauer, J. C., Cantley, L. C., and Yaffe, M. B. (2003) Scansite 2.0: pro-
teome-wide prediction of cell signaling interactions using short sequence
motifs. Nucleic Acids Res. 31, 3635–3641
27. Storz, P., Döppler, H., and Toker, A. (2004) Protein kinase C selectively
regulates protein kinase D-dependent activation of NF-B in oxidative
stress signaling. Mol. Cell. Biol. 24, 2614–2626
28. Storz, P., Döppler, H., and Toker, A. (2004) Activation loop phosphoryla-
tion controls protein kinase D-dependent activation of nuclear factor B.
Mol. Pharmacol. 66, 870–879
29. Döppler, H., and Storz, P. (2007) A novel tyrosine phosphorylation site in
protein kinase D contributes to oxidative stress-mediated activation.
J. Biol. Chem. 282, 31873–31881
30. Rapacciuolo, A., Suvarna, S., Barki-Harrington, L., Luttrell, L. M., Cong,
M., Lefkowitz, R. J., and Rockman, H. A. (2003) Protein kinase A and G
protein-coupled receptor kinase phosphorylation mediates -1 adrener-
gic receptor endocytosis through different pathways. J. Biol. Chem. 278,
35403–35411
31. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., and Shoelson, S. E. (1998)
Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441–450
32. Kratz,C.P.,Niemeyer,C.M.,Castleberry,R.P.,Cetin,M.,Bergsträsser,E.,
Emanuel,P.D.,Hasle,H.,Kardos,G.,Klein,C.,Kojima,S.,Stary,J.,Trebo,
M., Zecca, M., Gelb, B. D., Tartaglia, M., and Loh, M. L. (2005) The mu-
tational spectrum of PTPN11 in juvenile myelomonocytic leukemia and
Noonan syndrome/myeloproliferative disease. Blood 106, 2183–2185
33. Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., and Neel, B. G.
(2005) Diverse biochemical properties of Shp2 mutants. Implications for
disease phenotypes. J. Biol. Chem. 280, 30984–30993
34. Enns, L. C., Bible, K. L., Emond, M. J., and Ladiges, W. C. (2010) Mice
lacking the C subunit of PKA are resistant to angiotensin II-induced
cardiac hypertrophy and dysfunction. BMC Res. Notes 3, 307
35. Wang L., Burmeister B.T., Johnson K.R., Baillie G.S., Karginov A.V., Skid-
gel R.A., O’Bryan J.P., Carnegie G.K. (2015) UCR1C is a novel activator of
phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte
hypertrophy. Cell Signal. 27, 908–922
36. Fielitz, J., Kim, M. S., Shelton, J. M., Qi, X., Hill, J. A., Richardson, J. A.,
Bassel-Duby,R.,andOlson,E.N.(2008)RequirementofproteinkinaseD1
for pathological cardiac remodeling. Proc. Natl. Acad. Sci. U.S.A. 105,
3059–3063
37. Appert-Collin,A.,Cotecchia,S.,Nenniger-Tosato,M.,Pedrazzini,T.,and
Diviani,D.(2007)TheA-kinaseanchoringprotein(AKAP)-Lbc-signaling
complexmediatesalpha1adrenergicreceptor-inducedcardiomyocytehy-
pertrophy. Proc. Natl. Acad. Sci. U.S.A. 104, 10140–10145
PKAPhosphorylationInhibitsShp2PTPActivity
MAY8,2015•VOLUME290•NUMBER19 JOURNALOFBIOLOGICALCHEMISTRY 12067
 
a
t
 
U
C
L
 
L
i
b
r
a
r
y
 
S
e
r
v
i
c
e
s
 
o
n
 
J
u
l
y
 
2
9
,
 
2
0
1
5
h
t
t
p
:
/
/
w
w
w
.
j
b
c
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Graeme K. Carnegie
and Gold, Randal A. Skidgel, John P. O'Bryan 
Brian T. Burmeister, Li Wang, Matthew G.
  
Activity and Modulates Ligand Specificity
Shp2 Protein Inhibits Its Phosphatase 
Protein Kinase A (PKA) Phosphorylation of
Signal Transduction:
doi: 10.1074/jbc.M115.642983 originally published online March 23, 2015
2015, 290:12058-12067. J. Biol. Chem. 
  
  10.1074/jbc.M115.642983 Access the most updated version of this article at doi: 
  
. JBC Affinity Sites Find articles, minireviews, Reflections and Classics on similar topics on the 
  Alerts: 
  
  When a correction for this article is posted •  
  When this article is cited •  
 to choose from all of JBC's e-mail alerts Click here
  
  http://www.jbc.org/content/290/19/12058.full.html#ref-list-1
This article cites 37 references, 18 of which can be accessed free at
 
a
t
 
U
C
L
 
L
i
b
r
a
r
y
 
S
e
r
v
i
c
e
s
 
o
n
 
J
u
l
y
 
2
9
,
 
2
0
1
5
h
t
t
p
:
/
/
w
w
w
.
j
b
c
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 